HUMACYTE GLOBAL, INC. – Trademark Portfolio
Entity Type: 03
HUMACYTE GLOBAL, INC. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 8 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 2 trademarks are registered and 5 are pending. Notable registered marks include SYMVESS and HUMACYTE. The owner is based in DURHAM, NC.
2525 E. NC Highway 54
DURHAM, NC 27713
Showing of trademarks Trademarks
Trademark Classifications
HUMACYTE GLOBAL, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does HUMACYTE GLOBAL, INC. have?
HUMACYTE GLOBAL, INC. has 10 U.S. trademarks filed with the USPTO. Of these, 2 registered, 5 pending, 2 abandoned, 1 cancelled.
What trademark classes does HUMACYTE GLOBAL, INC. file in?
HUMACYTE GLOBAL, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.
What are HUMACYTE GLOBAL, INC.'s most well-known trademarks?
HUMACYTE GLOBAL, INC.'s registered trademark portfolio includes well-known marks such as SYMVESS and HUMACYTE. These are among 2 currently registered trademarks in the portfolio.
What is HUMACYTE GLOBAL, INC.'s trademark registration success rate?
HUMACYTE GLOBAL, INC. has a 40% trademark registration rate, with 2 out of 5 resolved applications resulting in successful registration. Currently, 5 applications are pending review.